Blair William & Co. IL Purchases 1,004 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Blair William & Co. IL boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.0% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 25,855 shares of the company’s stock after purchasing an additional 1,004 shares during the period. Blair William & Co. IL’s holdings in Medpace were worth $10,648,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Medpace by 5.9% in the fourth quarter. Vanguard Group Inc. now owns 2,556,443 shares of the company’s stock valued at $783,626,000 after buying an additional 142,591 shares during the last quarter. TD Asset Management Inc lifted its holdings in Medpace by 22.9% during the 1st quarter. TD Asset Management Inc now owns 574,149 shares of the company’s stock valued at $232,042,000 after purchasing an additional 107,108 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Medpace by 38.3% during the 2nd quarter. Renaissance Technologies LLC now owns 443,588 shares of the company’s stock valued at $182,692,000 after purchasing an additional 122,800 shares during the last quarter. Epoch Investment Partners Inc. boosted its position in Medpace by 15.3% during the first quarter. Epoch Investment Partners Inc. now owns 406,446 shares of the company’s stock worth $164,265,000 after purchasing an additional 53,983 shares during the period. Finally, Bessemer Group Inc. increased its holdings in shares of Medpace by 1.6% in the first quarter. Bessemer Group Inc. now owns 394,834 shares of the company’s stock valued at $159,572,000 after purchasing an additional 6,137 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. William Blair restated an “outperform” rating on shares of Medpace in a research note on Wednesday, September 11th. TD Cowen reduced their price objective on Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a research note on Wednesday. Robert W. Baird decreased their price objective on Medpace from $469.00 to $430.00 and set an “outperform” rating on the stock in a report on Wednesday, July 24th. Finally, Truist Financial started coverage on Medpace in a report on Thursday, August 1st. They set a “hold” rating and a $415.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $423.00.

Medpace Stock Performance

MEDP opened at $369.18 on Friday. Medpace Holdings, Inc. has a 52-week low of $227.21 and a 52-week high of $459.77. The firm has a market cap of $11.44 billion, a P/E ratio of 37.63, a price-to-earnings-growth ratio of 1.74 and a beta of 1.36. The business’s fifty day moving average is $379.70 and its 200-day moving average is $392.28.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. The firm had revenue of $528.10 million for the quarter, compared to the consensus estimate of $528.41 million. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The business’s revenue for the quarter was up 14.6% on a year-over-year basis. During the same period in the prior year, the company posted $1.93 earnings per share. On average, research analysts predict that Medpace Holdings, Inc. will post 11.66 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.